Alirocumab (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023
|出版日期||內容資訊||英文 91 Pages
|Alirocumab(急性冠狀動脈症候群)- 預測與市場分析 Alirocumab (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023|
|出版日期: 2014年07月31日||內容資訊: 英文 91 Pages||
GlobalData has released its new PharmaPoint Drug Evaluation report, "Alirocumab (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023". The current ACS market - primarily comprised of antithrombotics, antihypertensives, and statins - is flush with well-established standard-of-care therapies, many of which are generic. Therefore, the pipeline therapies that show the most promise exploit novel mechanisms of action and target orphan biochemical pathways. The ACS market will be driven by an aging population with a preponderance of lifestyle-based diseases, such as obesity, and the growing prevalence of metabolic disorders such as diabetes. The expansion of biologics into the ACS mainstream during the ten year forecast period is expected to significantly and fundamentally alter the ACS market, both medically and financially.
The PCSK9 field is flush with new mAbs. In its current state, GlobalData expects that alirocumab will be the second-to-market PCSK9, following Amgen's PCSK9 mAb, evolocumab. GlobalData anticipates that Pfizer's PCSK9, bococizumab, which is entering Phase III later than these Sanofi/Regeneron and Amgen mAbs, will be third to market. These companies are designing complex, outcomes-based, Phase III clinical trials in an effort to show that the PCSK9 mAbs can effectively reduce the risk of occurrence of cardiovascular events in addition to reducing plasma LDL-C levels.